Current regulatory and scientific considerations for approving biosimilars in Iran
نویسندگان
چکیده
منابع مشابه
Biosimilars: Key regulatory considerations and similarity assessment tools
A biosimilar drug is defined in the US Food and Drug Administration (FDA) guidance document as a biopharmaceutical that is highly similar to an already licensed biologic product (referred to as the reference product) notwithstanding minor differences in clinically inactive components and for which there are no clinically meaningful differences in purity, potency, and safety between the two prod...
متن کاملNCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.
Biologics are essential to oncology care. As patents for older biologics begin to expire, the United States is developing an abbreviated regulatory process for the approval of similar biologics (biosimilars), which raises important considerations for the safe and appropriate incorporation of biosimilars into clinical practice for patients with cancer. The potential for biosimilars to reduce the...
متن کاملa framework for identifying and prioritizing factors affecting customers’ online shopping behavior in iran
the purpose of this study is identifying effective factors which make customers shop online in iran and investigating the importance of discovered factors in online customers’ decision. in the identifying phase, to discover the factors affecting online shopping behavior of customers in iran, the derived reference model summarizing antecedents of online shopping proposed by change et al. was us...
15 صفحه اولRegulatory guidelines for biosimilars in Malaysia.
The biosimilars sector continues to attract huge interest and controversy. Biosimilars are new biopharmaceuticals that are "similar" but not identical to the innovator product. Characteristics of biopharmaceuticals are closely related to the manufacturing process, which implies that the products cannot be exactly duplicated. Minuscule differences in the product's structure and manufacturing pro...
متن کاملBiosimilars in oncology: current and future perspectives
The healthcare burden of cancer Cancer places a signifi cant, and growing, burden on healthcare systems around the world. Improved therapies and changing demographics are conspiring to increase the already considerable drain on resources. On the one hand, population growth and ageing will increase the number of new cancer cases in the coming years [1]; on the other, advances in diagnosis and ma...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biologicals
سال: 2011
ISSN: 1045-1056
DOI: 10.1016/j.biologicals.2011.06.019